Chuanning Biology released its 2026 interim report, with net profit attributable to the parent company of 278 million yuan, a decrease of 38.99% compared with the same period last year. The company's total operating revenue was 2.098 billion yuan, down 10.68% year-on-year; net cash inflow from operating activities was 775 million yuan. The latest gross margin was 26.31%, a decrease of 9.56 percentage points from the same period last year; the latest return on equity was 3.48%, a decrease of 2.38 percentage points from the same period last year. The company's diluted earnings per share was 0.12 yuan, down 40.00% year-on-year.
Yili Chuanning Biotechnology Co. Ltd. ANet profit down 38.99% and revenue down 10.68% in interim report.